IDH1 and acute myeloid leukemia: Recently, new drugs have been approved for use, including Enasidenib and Ivosidenib—inhibitors targeting recurrent mutations in IDH1/2 genes, respectively, thus extending the therapeutic landscape for AML [5,6].